Abstract
Ischemia and reperfusion injury (IRI) is a prime antigen-independent inflammatory factor in the dysfunction of liver transplants. Despite improved allograft preservation and surgical techniques, IRI can still cause up to 10% of early orthotopic liver transplant failure, and can lead to a higher incidence of both acute and chronic graft rejection. Recent advances in gene transfer have resulted in a reduction or inhibition of liver IRI in several experimental models. This review summarizes the development of existing and potential approaches to human gene therapy. These studies aimed at ameliorating I/R injury are focused on the cytoprotective effects in transplant recipients by induction of anti-apoptotic or protective genes, immunoregulation of cytokines or blockade of signaling transduction pathway in graft cells. Although this review focuses on the application of viral mediated gene therapy, new non-viral gene transfer techniques, such as RNA interference (RNAi) application, are discussed. Future advances in gene therapy technology should result in fewer side effects, and thus more acceptable for clinical application, and more successful for organ transplantation.
Keywords: Ischemia/Reperfusion Injury, Liver, Transplantation, Gene Therapy, Heme Oxygenase-1, Cytokines, Costimulation
Current Pharmaceutical Design
Title: Gene Therapy in Liver Ischemia and Reperfusion Injury
Volume: 12 Issue: 23
Author(s): Bibo Ke, Gerald S. Lipshutz and Jerzy W. Kupiec-Weglinski
Affiliation:
Keywords: Ischemia/Reperfusion Injury, Liver, Transplantation, Gene Therapy, Heme Oxygenase-1, Cytokines, Costimulation
Abstract: Ischemia and reperfusion injury (IRI) is a prime antigen-independent inflammatory factor in the dysfunction of liver transplants. Despite improved allograft preservation and surgical techniques, IRI can still cause up to 10% of early orthotopic liver transplant failure, and can lead to a higher incidence of both acute and chronic graft rejection. Recent advances in gene transfer have resulted in a reduction or inhibition of liver IRI in several experimental models. This review summarizes the development of existing and potential approaches to human gene therapy. These studies aimed at ameliorating I/R injury are focused on the cytoprotective effects in transplant recipients by induction of anti-apoptotic or protective genes, immunoregulation of cytokines or blockade of signaling transduction pathway in graft cells. Although this review focuses on the application of viral mediated gene therapy, new non-viral gene transfer techniques, such as RNA interference (RNAi) application, are discussed. Future advances in gene therapy technology should result in fewer side effects, and thus more acceptable for clinical application, and more successful for organ transplantation.
Export Options
About this article
Cite this article as:
Ke Bibo, Lipshutz S. Gerald and Kupiec-Weglinski W. Jerzy, Gene Therapy in Liver Ischemia and Reperfusion Injury, Current Pharmaceutical Design 2006; 12 (23) . https://dx.doi.org/10.2174/138161206777947669
DOI https://dx.doi.org/10.2174/138161206777947669 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Oxidative Stress on Necrotizing Enterocolitis in Very Low Birth Weight Infants
Current Pediatric Reviews Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology Protective Effects of Dietary Flavonoids in Diabetic Induced Retinal Neurodegeneration
Current Drug Targets Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Regulatory Mechanism miR-302a-3p/E2F1/SNHG3 Axis in Nerve Repair Post Cerebral Ischemic Stroke
Current Neurovascular Research Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Caveolin-1 in Stroke Neuropathology and Neuroprotection: A Novel Molecular Therapeutic Target for Ischemic-Related Injury
Current Vascular Pharmacology Disruption of Circadian Rhythms and Sleep in Critical Illness and its Impact on Innate Immunity
Current Pharmaceutical Design Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design